Honey Schaumburg, PA
Physician Assistant · Fort Smith, ARNPI 1912279290
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $260,089 of the $396,656 with a category attached, or 65.6%. 29 manufacturers reported payments, led by Johnson & Johnson at 28.4% of the total. 2025 is the largest year on record at $110,609, 4.5 times the $24,529 reported in 2021. Among physician assistant clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,218 payments — averaging $325.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$113K
- Janssen Scientific Affairs, LLC$63K
- AbbVie$51K
- Arcutis Biotherapeutics, Inc.$50K
- UCB, Inc.$34K
- Lilly USA, LLC$29K
- plus $56K from 23 others
What the payments were for
- Consulting fees$44,56811%
- Speaking & faculty fees$260,08966%
- Travel & lodging$69,89018%
- Food & beverage$21,6285%
- Education$4820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 192 | $112,711 |
| Janssen Scientific Affairs, LLC | 81 | $63,316 |
| AbbVie | 133 | $51,457 |
| Arcutis Biotherapeutics, Inc. | 75 | $50,284 |
| UCB, Inc. | 90 | $33,910 |
| Lilly USA, LLC | 119 | $29,101 |
| Dermavant Sciences, Inc. | 83 | $28,251 |
| Galderma Laboratories, L.p. | 61 | $8,812 |
| Organon | 17 | $4,960 |
| Amgen | 48 | $4,036 |
| Novartis | 54 | $2,935 |
| LEO Pharma Inc. | 35 | $1,489 |
| E.r. Squibb & Sons, L.L.C. | 32 | $1,143 |
| Sanofi | 25 | $706 |
| Sun Pharmaceutical Industries Inc. | 33 | $661 |
| Pfizer | 41 | $644 |
| Regeneron Healthcare Solutions, Inc. | 28 | $582 |
| Incyte Corporation | 31 | $578 |
| Kowa Pharmaceuticals America, Inc. | 1 | $300 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $270 |
| VYNE Pharmaceuticals Inc. | 4 | $141 |
| Mayne Pharma Commercial LLC | 9 | $131 |
| Genentech USA, Inc. | 2 | $47 |
| Kerecis Limited | 2 | $41 |
| Biofrontera Inc. | 3 | $39 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Almirall LLC | 2 | $31 |
| Boehringer Ingelheim | 1 | $31 |
| Sandoz | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$396,656 in reported general payments places this provider in the 95th percentile of 451 physician assistant providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 29 | $661,815 |
| TremfyaGuselkumab | 36 | $492,563 |
| Cosentyx Unoready PenSecukinumab | 40 | $465,186 |
| OtezlaApremilast | 76 | $356,510 |
| Dupixent PenDupilumab | 71 | $284,822 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 19 | $276,405 |
| Humira(Cf) PenAdalimumab | 20 | $222,393 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $162,961 |
| Taltz AutoinjectorIxekizumab | 23 | $157,093 |
| Dupixent SyringeDupilumab | 31 | $117,845 |
| RinvoqUpadacitinib | 13 | $97,175 |
| XolairOmalizumab | 26 | $72,057 |
| Ketoconazole | 262 | $4,742 |
| Doxycycline Hyclate | 244 | $4,545 |
| Calcipotriene | 28 | $4,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $112,711 | $492,56336 claims |
| AmgenOtezla | $4,036 | $356,51076 claims |
| AbbVieRinvoq | $51,457 | $97,17513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 451 physician assistant providers in Arkansas.
Other physician assistant in Fort Smith
- Benton LoggainsFort Smith$39K
- Bryce BassFort Smith$11K
- Kayla MouryFort Smith$11K
- Melanie MyersFort Smith$10K
- Lauren SatterfieldFort Smith$7K
- Adrienne EasterlingRogers$366K
- Katherine RossLittle Rock$44K
- Monte DouglasJacksonville$38K
- Anna StilinovicFayetteville$32K
- Timothy BookerLittle Rock$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.